× Author Guidelines Publishing Ethics Join As Reviewer Advertise Current Issue Archive Submit Article Abstracting And Indexing Editorial Board Contact Editor-in-Chief Scope of the Journal About the Journal


JAPER is indexed in SCOPUS

New-onset type 2 DM risk in dyslipidemia and stroke patients due to simvastatin use


Ema Pristi Yunita , Widya Pratiwi Suryanti , Didi Candradikusuma

Abstract

Simvastatin is a therapy management for dyslipidemia and stroke, which are prevalent in Indonesia. These drugs are very effective in reducing the incidence of cardiovascular disease and mortality in high-risk patients. However, long-term use of simvastatin may lead to new problems, such as the risk of new-onset type 2 DM. This study aims to monitor the blood glucose profile to determine the risk of new-onset type 2 DM. This study is observational with a prospective one-group pre-test and post-test design conducted at the outpatient polyclinic of UNISMA Islamic Hospital Malang from February to June 2018. The sample consisted of patients who received a long-term simvastatin therapy dose of 20 mg. A paired t-test was performed when the data were normally distributed to determine the significance of FPG and HbA1c levels changes. The results showed that the increase in fasting plasma glucose (FPG) levels at the first and third months was not statistically significant (97.44 mg/dL vs. 100.33 mg/dL; p = 0.196). Similarly, the increase in HbA1c levels was not statistically significant (6.79% vs. 7.53%; p = 0.076). However, the results of FPG and HbA1c showed that all patients (27 people) have the possibility of experiencing new-onset type 2 DM. In short, routine intake of 20 mg simvastatin with a minimum usage duration of 6 months has caused 27 patients to experience a new-onset type 2 DM.


How to cite this article:
Vancouver
Yunita E P, Suryanti W P, Candradikusuma D. New-onset type 2 DM risk in dyslipidemia and stroke patients due to simvastatin use. J Adv Pharm Educ Res. 2021;11(3):137-43. https://doi.org/10.51847/qvunlqV9fN
APA
Yunita, E. P., Suryanti, W. P., & Candradikusuma, D. (2021). New-onset type 2 DM risk in dyslipidemia and stroke patients due to simvastatin use. Journal Of Advanced Pharmacy Education And Research, 11(3),137-143. https://doi.org/10.51847/qvunlqV9fN
Citation Formats:


Contact SPER Publications


SPER Publications and Solutions Pvt. Ltd.

HD - 236,
Near The Shri Ram Millenium School,
Sector 135,
Noida-Greater Noida Expressway,
Noida-201301 [Delhi-NCR] India